Barbara McLaughlan discusses England's Cancer Drugs Fund (CDF) and suggests ways of securing a new, sustainable assessment and funding model for cancer medicines.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
